Market Overview

Portola Pharma Shares Under Pressure After FDA Extension

Portola Pharma Shares Under Pressure After FDA Extension

Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares are down Tuesday after the company's Friday announcement that the FDA has extended its review period for the biologics license application for AndexXa, an anticoagulant antidote product candidate, by 90 days.

In August 2016, the company received complete response letter delaying the therapy's approval. The drug watchdog had sought additional data to support the inclusion of edoxaban and enoxaparin in the label, while it also needed to finalize its review of the clinical amendments to the company's post-market commitments.

The Analyst

William Blair analyst Matt Phipps has an Outperform rating on Portola Pharma.

The Thesis

The recent extension of the review period is to allow the FDA time to review additional information recently submitted by the company, and further discuss labeling and post-marketing commitments, Phipps said in a Tuesday morning note.

The submission in question included additional data requested by the FDA from the ANNEXA-4 study, which evaluated AndexXa in patients on a Factor Xa inhibitor with an acute major bleeding episode, the analyst said.

Notwithstanding the setback, which has led to disappointment among investors, Phipps said he continues to believe AndexXa will receive FDA approval, with a decision date of May 4.

William Blair revised its commercial estimates for AndexXa based on updated timelines in 2018, with the U.S. launch now likely toward the end of the second quarter and the European launch expected in the near term. 

This expectation, combined with the commercial launch of Bevyxxa, meant for the prophylaxis of venous thromboembolism, provides significant upside potential to the current share price of Portola Pharma, Phipps said. 

Bevyxxa was approved by the FDA on June 23, 2017.

The Price Action

Shares of Portola Pharma are up about 145 percent year-to-date until Dec. 22.

The shares were shedding 8.28 percent to $50.32 at last check in reaction to the FDA extension. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

The Companies That Led 2017's Biotech Rally

Latest Ratings for PTLA

Oct 2019MaintainsBuy
Aug 2019AssumesNeutral
Jul 2019AssumesNeutral

View More Analyst Ratings for PTLA
View the Latest Analyst Ratings

Posted-In: Matt PhippsAnalyst Color Biotech News Reiteration FDA Analyst Ratings General Best of Benzinga


Related Articles (PTLA)

View Comments and Join the Discussion!

Latest Ratings

CNCDeutsche BankMaintains60.0
MTGDeutsche BankMaintains18.5
SHWDeutsche BankMaintains640.0
BYDDeutsche BankMaintains35.0
CEDeutsche BankMaintains124.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Analyst: BlackBerry Owes Q3 Beat To Licensing, Continued SaaS Pivot

A Cryptocannabis Rally: India Globalization Capital Spikes 100%